Robert Stuart to Adult
This is a "connection" page, showing publications Robert Stuart has written about Adult.
Connection Strength
0.492
-
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 10; 85:106197.
Score: 0.046
-
Ankle Lateral Ligament Augmentation Versus the Modified Brostr?m-Gould Procedure: A 5-Year Randomized Controlled Trial. Am J Sports Med. 2019 03; 47(3):659-666.
Score: 0.045
-
Primary ankle ligament augmentation versus modified Brostrom-Gould procedure: a 2-year randomized controlled trial. ANZ J Surg. 2015 Jan; 85(1-2):44-8.
Score: 0.033
-
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov; 52(11):2375-81.
Score: 0.028
-
Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. 2003 Dec; 35(8):3089-92.
Score: 0.016
-
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematol Oncol. 2020 Aug; 38(3):353-362.
Score: 0.012
-
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
Score: 0.012
-
Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol. 1999 Jul; 16(2):95-103.
Score: 0.011
-
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1744-1755.
Score: 0.011
-
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemother Pharmacol. 2019 07; 84(1):163-173.
Score: 0.011
-
Malignant ovarian germ cell tumours -- a survival and prognostic analysis. Acta Oncol. 1999; 38(4):455-60.
Score: 0.011
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
Score: 0.011
-
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85.
Score: 0.011
-
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398.
Score: 0.011
-
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 08; 24(8):1581-1589.
Score: 0.011
-
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol. 2016 08 17; 9(1):71.
Score: 0.009
-
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
Score: 0.009
-
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
Score: 0.009
-
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015; 56(9):2569-78.
Score: 0.009
-
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015 Feb; 100(2):231-7.
Score: 0.008
-
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62.
Score: 0.008
-
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10; 32(29):3264-74.
Score: 0.008
-
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. Biol Blood Marrow Transplant. 2014 Feb; 20(2):222-8.
Score: 0.008
-
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60.
Score: 0.007
-
Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leuk Lymphoma. 2012 Dec; 53(12):2444-8.
Score: 0.007
-
Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst. 1991 Dec 18; 83(24):1806-12.
Score: 0.007
-
Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991 Dec; 302(6):369-73.
Score: 0.007
-
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol. 2011 Aug; 86(8):699-701.
Score: 0.007
-
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res. 2011 May 15; 17(10):3388-97.
Score: 0.006
-
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.
Score: 0.006
-
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1176-81.
Score: 0.006
-
Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 2011 Feb; 28(2):150-9.
Score: 0.006
-
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010 Dec; 151(5):430-4.
Score: 0.006
-
Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010 Aug; 85(8):627-9.
Score: 0.006
-
Translocation t(3;8;9)(p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: a unique case and review of the literature. Leuk Res. 2010 Nov; 34(11):1543-4.
Score: 0.006
-
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33.
Score: 0.006
-
Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 07; 150(7):455-64.
Score: 0.006
-
Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. Aliment Pharmacol Ther. 2008 Apr; 27(8):666-77.
Score: 0.005
-
Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl. 2007 Jun; 13(6):904-12.
Score: 0.005
-
Hematologic and cytogenetic remission of 5q-refractory anemia after syngeneic bone marrow transplantation. Am J Med. 1986 Mar; 80(3):503-7.
Score: 0.005
-
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004 Oct; 40(15):2260-8.
Score: 0.004
-
High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat. 2000 Aug; 62(3):237-44.
Score: 0.003
-
Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. Am J Med. 1980 Jun; 68(6):876-85.
Score: 0.003
-
Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. 2000 Feb; 17(1):39-46.
Score: 0.003
-
Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000 Jan; 18(1):148-57.
Score: 0.003
-
Primary gastric non-Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Ann Oncol. 1999 Dec; 10(12):1441-9.
Score: 0.003
-
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 1999 Jul; 5(7):1723-30.
Score: 0.003
-
Breast cancer in the eastern province of Saudi Arabia. Med Oncol. 1998 Dec; 15(4):241-7.
Score: 0.003
-
Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation. Am J Hematol. 1998 Apr; 57(4):326-30.
Score: 0.003
-
Disposition of folic acid and its metabolites: a comparison with leucovorin. Clin Pharmacol Ther. 1994 May; 55(5):501-8.
Score: 0.002
-
CD34+ and CD33+ stem cells: predictors of hematologic recovery? Prog Clin Biol Res. 1992; 377:505-12.
Score: 0.002
-
A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study. Cancer. 1990 Apr 15; 65(8):1700-3.
Score: 0.002
-
The occurrence of a peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Am J Surg Pathol. 1988 Jan; 12(1):64-70.
Score: 0.001
-
Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res. 1987 Jun 15; 47(12):3309-16.
Score: 0.001
-
Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 1986 Jul 17; 315(3):141-7.
Score: 0.001
-
Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood. 1985 Jun; 65(6):1504-10.
Score: 0.001
-
Energy requirements of parenterally fed bone marrow transplant recipients. JPEN J Parenter Enteral Nutr. 1985 Mar-Apr; 9(2):139-43.
Score: 0.001
-
Nutritional assessment by isotope dilution analysis of body composition. Am J Clin Nutr. 1984 Oct; 40(4):847-54.
Score: 0.001